纤维肌发育不良患者颈动脉支架置入术的结局
基于血管质量倡议数据库2012年12月至2021年5月的回顾性分析,按年龄、性别和临床表现1:1匹配,比较纤维肌发育不良(FMD)与动脉粥样硬化患者行颈动脉支架置入术(CAS)的结局。FMD组55例,围手术期卒中、短暂性脑缺血发作或30天死亡率与非FMD组无差异,两组1年生存率均为100%,FMD组随访期间无死亡或再干预。
要点
- FMD患者行CAS技术成功率高,围手术期神经并发症发生率低
- FMD组与非FMD组围手术期卒中、TIA或30天死亡率无差异
- 两组1年生存率均为100%,FMD组随访期间无死亡或再干预
核心结论
- FMD患者行CAS是可行且安全的手术,技术成功率高、神经并发症发生率低,1年随访临床结局良好。
研究设计与样本
- 回顾性分析,使用血管质量倡议数据库2012年12月至2021年5月数据,纳入因动脉粥样硬化和FMD行CAS的患者,按年龄、性别和临床表现1:1匹配。
主要发现
- 匹配后FMD组55例,平均年龄58.7±14岁,62%为女性,69%为白人,平均体重指数28±6 kg/m2。
- FMD组高血压55% vs 非FMD组82%(P = .002),吸烟35% vs 80%(P < .001),糖尿病13% vs 45%(P < .001),冠心病9% vs 45%(P < .001)。
- FMD组既往TIA 39例(71%)、卒中31例(57%),距本次手术平均间隔160天;23例(42%)病变位于第二颈椎水平以上。
- FMD组经股动脉入路43例(78%),远端栓塞保护40例(93%),血流逆转9例(23%),局部麻醉58%;3例(6%)发生入路部位并发症,均非手术治疗。
- FMD组与非FMD组围手术期卒中、TIA或30天死亡率无差异;两组住院时间相似,1年生存率均为100%;FMD组均无神经并发症出院,50例(91%)接受双联抗血小板治疗;中位随访328天(四分位距1-732天),随访期间无死亡或再干预。
临床怎么用
- 作者认为,FMD患者行CAS是可行且安全的手术,技术成功率高、神经并发症发生率低,1年随访临床结局良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fibromuscular dysplasia (FMD) is a noninflammatory arterial disease that affects the extracranial carotid arteries in young patients. The ideal treatment of FMD has continued to be debated, and the role of carotid artery stenting (CAS) is controversial. The aim of the present study was to assess the feasibility and outcomes of CAS for patients with FMD. METHODS: A retrospective analysis of patients who had undergone CAS was performed using the Vascular Quality Initiative database from December 2012 to May 2021. Patients who had undergone CAS for atherosclerosis and FMD were included and matched 1:1 by age, gender, and clinical presentation. The demographics, clinical parameters, and procedural data were analyzed. The end points included postoperative stroke and transient ischemic attack (TIA), and adverse events (perioperative and 1-year mortality, neurologic changes, access site complications, hematoma or bleeding, infection, congestive heart failure, arrhythmia, myocardial infarction, reperfusion symptoms), and hospital length of stay. RESULTS: After matching, 55 patients had undergone CAS for FMD (mean age, 58.7 ± 14 years; 62% women; 69% White; mean body mass index, 28 ± 6 kg/m2). Most of these procedures (69%) were elective. The FMD group had had a lower rate of hypertension (55% vs 82%; P = .002), smoking (35% vs 80%; P < .001), diabetes (13% vs 45%; P < .001), and coronary artery disease (9% vs 45%; P < .001) compared with the non-FMD group. In the FMD group, prior TIA and stroke was identified in 39 (71%) and 31 (57%) patients, respectively. The mean interval from a prior stroke or TIA to the index surgery was 160 days. Additionally, 23 patients (42%) had had anatomically high lesions above the level of the second cervical vertebra. In the FMD group, the transfemoral approach was used for 43 patients (78%), with distal embolic protection used for 40 patients (93%). Flow reversal was used for nine patients (23%). Most cases were performed with local anesthesia (58%). Three patients (6%) in the FMD group had had access site complications that were managed nonoperatively. No differences were found between the FMD and non-FMD groups in perioperative stroke, TIA, or 30-day mortality. The length of stay was similar between the two groups, and the 1-year survival was 100% for both groups. All the patients in the FMD group were discharged without neurologic complications, and 50 patients (91%) were receiving dual antiplatelet therapy. The median follow-up was 328 days (interquartile range, 1-732 days) with no mortality or reinterventions during follow-up. CONCLUSIONS: CAS for FMD is a feasible and safe procedure with favorable technical success, a low incidence of neurologic complications, and good clinical outcomes at 1 year of follow-up.
引用
- Porras-Colon J, Scott CK, Pizano A, et al. Outcomes of carotid stenting in patients with fibromuscular dysplasia. J Vasc Surg. 2022. PMID: 36400362. doi:10.1016/j.jvs.2022.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。